JP2018535432A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535432A5
JP2018535432A5 JP2018536062A JP2018536062A JP2018535432A5 JP 2018535432 A5 JP2018535432 A5 JP 2018535432A5 JP 2018536062 A JP2018536062 A JP 2018536062A JP 2018536062 A JP2018536062 A JP 2018536062A JP 2018535432 A5 JP2018535432 A5 JP 2018535432A5
Authority
JP
Japan
Prior art keywords
configuration
ctc
nuclear
therapy
nucleated cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018536062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535432A (ja
JP6936231B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/053387 external-priority patent/WO2017053763A2/en
Publication of JP2018535432A publication Critical patent/JP2018535432A/ja
Publication of JP2018535432A5 publication Critical patent/JP2018535432A5/ja
Application granted granted Critical
Publication of JP6936231B2 publication Critical patent/JP6936231B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018536062A 2015-09-25 2016-09-23 転移性去勢抵抗性前立腺癌（ｍＣＲＰＣ）患者における治療選択のためのバイオマーカーとしてのアンドロゲン受容体バリアント７ Active JP6936231B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233206P 2015-09-25 2015-09-25
US62/233,206 2015-09-25
PCT/US2016/053387 WO2017053763A2 (en) 2015-09-25 2016-09-23 ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)

Publications (3)

Publication Number Publication Date
JP2018535432A JP2018535432A (ja) 2018-11-29
JP2018535432A5 true JP2018535432A5 (https=) 2019-10-31
JP6936231B2 JP6936231B2 (ja) 2021-09-15

Family

ID=58387342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536062A Active JP6936231B2 (ja) 2015-09-25 2016-09-23 転移性去勢抵抗性前立腺癌（ｍＣＲＰＣ）患者における治療選択のためのバイオマーカーとしてのアンドロゲン受容体バリアント７

Country Status (9)

Country Link
US (2) US20190285636A1 (https=)
EP (1) EP3353553B1 (https=)
JP (1) JP6936231B2 (https=)
CN (3) CN108450001A (https=)
AU (1) AU2016325617A1 (https=)
CA (1) CA2999911A1 (https=)
EA (1) EA201890816A1 (https=)
IL (1) IL258318A (https=)
WO (1) WO2017053763A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101926117B1 (ko) * 2017-08-18 2018-12-06 주식회사 싸이토젠 안드로겐 수용체의 변이체 기반 전립선암환자 스크리닝 방법
US20220184086A1 (en) * 2019-03-28 2022-06-16 Cardiff Oncology, Inc. Plk1 inhibitors and psa levels in prostate cancer
EP4160181A4 (en) * 2020-05-28 2024-08-07 Wang, Daoxiang METHOD FOR PREPARING MULTIPLE STAINING SECTIONS FOR A CYTOPATHOLOGY SAMPLE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9671405B2 (en) * 2012-09-19 2017-06-06 Cornell University Identifying taxane sensitivity in prostate cancer patients
US20160266127A1 (en) * 2013-09-30 2016-09-15 Peter Kuhn Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
EA201691496A1 (ru) * 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EP3100052B1 (en) * 2014-01-30 2021-03-10 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies

Similar Documents

Publication Publication Date Title
Maheswaran et al. Circulating tumor cells: a window into cancer biology and metastasis
Siravegna et al. Integrating liquid biopsies into the management of cancer
Schneck et al. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients
Yap et al. Circulating tumor cells: a multifunctional biomarker
Keysar et al. Regulation of head and neck squamous cancer stem cells by PI3K and SOX2
JP6912064B2 (ja) 疾患の検出及び診断のための血液中の循環細胞バイオマーカーの使用並びにそれらを単離する方法
Li et al. Molecular characterization of circulating tumor cells—from bench to bedside
Mostert et al. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients
Schehr et al. High specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1
Economopoulou et al. Cancer of unknown primary origin in the genomic era: elucidating the dark box of cancer
Shan et al. Loss of stromal caveolin-1 expression: a novel tumor microenvironment biomarker that can predict poor clinical outcomes for pancreatic cancer
JP7692075B2 (ja) 循環細胞を用いて被検者における治療反応及び疾患の進行をモニターする方法
JP2019502384A5 (https=)
JP2020522697A5 (https=)
Nolan et al. Detection of apoptotic circulating tumor cells using in vivo fluorescence flow cytometry
Rink et al. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder
Halilovic et al. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study
Durendez-Saez et al. New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA
JP2018535432A5 (https=)
Hugen et al. Circulating tumor cells in genitourinary malignancies: an evolving path to precision medicine
Bou Zerdan et al. Liquid biopsies and minimal residual disease in lymphoid malignancies
Miyamoto et al. Cell-free and circulating tumor cell–based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?
Fischer Circulating tumor cells: seeing is believing
WO2017053763A3 (en) ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)
Harris et al. Quest for the ideal cancer biomarker: an update on progress in capture and characterization of circulating tumor cells